Bring us a deal like this Locust Walk as posted by
Post# of 72447
(Total Views: 509)
Posted On: 12/23/2019 5:20:14 PM
Bring us a deal like this Locust Walk as posted by djs7 at the swamp:
Locust Walk fasinumab deal completed for Regeneron with Asian Co. - peak sales < projected peak sales BOM
Interesting to know the estimated sales in those Asian regions, certainly not $500 million.
Fasinumab must have been headed to Phase 3:
fasinumab (REGN475) is a fully-humanized monoclonal antibody against nerve growth factor (NGF) in late-stage development for the treatment of musculoskeletal pain
The company finalized a term sheet with Mitsubishi Tanabe Pharmaceutical Corporation (MTPC) for the exclusive development and commercialization rights to fasinumab in Japan & other Asian countries.
Regeneron engaged Locust Walk’s Asia Team to assist with negotiations to expedite the closing of the definitive Collaboration Agreement with MTPC.Successful Outcome
On October 1, 2015, Regeneron and MTPC announced the signing of a Collaboration Agreement granting MTPC the exclusive right to develop and commercialize fasinumab in Japan, South Korea, Taiwan, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Myanmar, and Sri Lanka.
Regeneron will receive up to $55M in upfront and other near-term payments. The agreement provides for additional payments to Regeneron of up to $170M in R&D reimbursement payments and development milestones. Regeneron is also eligible for additional one-time purchase price adjustment payments of up to $100M total upon achievement of specified annual net sales.
This significant deal represents one of the largest single-product transactions for the Japan/Asia pharmaceutical market.
https://www.locustwalk.com/regeneron/
In addition, Teva gave Regeneron $250 million for a fasinumab deal everywhere except Asia and a 50% share.
:
https://www.evaluate.com/vantage/articles/new...anofi-pain
Note in the article: fasinumab peak sales are estimated @ $500m
Go IPIX!!!
Locust Walk fasinumab deal completed for Regeneron with Asian Co. - peak sales < projected peak sales BOM
Interesting to know the estimated sales in those Asian regions, certainly not $500 million.
Fasinumab must have been headed to Phase 3:
fasinumab (REGN475) is a fully-humanized monoclonal antibody against nerve growth factor (NGF) in late-stage development for the treatment of musculoskeletal pain
The company finalized a term sheet with Mitsubishi Tanabe Pharmaceutical Corporation (MTPC) for the exclusive development and commercialization rights to fasinumab in Japan & other Asian countries.
Regeneron engaged Locust Walk’s Asia Team to assist with negotiations to expedite the closing of the definitive Collaboration Agreement with MTPC.Successful Outcome
On October 1, 2015, Regeneron and MTPC announced the signing of a Collaboration Agreement granting MTPC the exclusive right to develop and commercialize fasinumab in Japan, South Korea, Taiwan, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Myanmar, and Sri Lanka.
Regeneron will receive up to $55M in upfront and other near-term payments. The agreement provides for additional payments to Regeneron of up to $170M in R&D reimbursement payments and development milestones. Regeneron is also eligible for additional one-time purchase price adjustment payments of up to $100M total upon achievement of specified annual net sales.
This significant deal represents one of the largest single-product transactions for the Japan/Asia pharmaceutical market.
https://www.locustwalk.com/regeneron/
In addition, Teva gave Regeneron $250 million for a fasinumab deal everywhere except Asia and a 50% share.
:
https://www.evaluate.com/vantage/articles/new...anofi-pain
Note in the article: fasinumab peak sales are estimated @ $500m
Go IPIX!!!
(6)
(1)